What Are Mesothelioma Clinical Trials?
Mesothelioma clinical trials are research studies that explore new treatment options and therapies for mesothelioma patients.
Many of today’s standard mesothelioma treatment options, such as chemotherapy and targeted radiation, were first tested in clinical trials before they were approved for widespread use.
- There are 80+ actively recruiting mesothelioma clinical studies nationwide as of October 2023.
- Clinical trials can’t start enrolling patients until a proposed treatment has been proven safe after years of lab research.
- Some mesothelioma clinical trials test a combination of different treatments, such as immunotherapy with radiation or chemotherapy.
- Trial participants will either get the new treatment, a placebo (a substance with no therapeutic benefit), or the standard treatment for comparison.
If you’re interested in accessing new treatments, talk to a doctor who specializes in mesothelioma to find trials you can join. Use our Free Doctor Match service to find mesothelioma specialists near you.
Find Mesothelioma Clinical Trials Near You
Use the dropdown menu below to find active mesothelioma clinical trials in your state and get help enrolling.
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance
- Pleural Effusion, Malignant
- Ascites, Malignant
- Mesothelioma
- xCures, Oakland, California
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase II Trial of Adcetris (Brentuximab Vedotin) in CD30+ Malignant Mesothelioma
- Malignant Mesothelioma
- Drug: Brentuximab Vedotin
- Other: Laboratory Biomarker Analysis
- M D Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma
- Mesothelioma
- Solitary Fibrous Tumor of the Pleura
- Mayo Clinic in Rochester, Rochester, Minnesota
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors
- Primary Peritoneal Carcinoma
- Non-small Cell Lung Cancer
- Mesothelioma
- Drug: PRO1184
- University of California Los Angeles Medical Center, Los Angeles, California
- University of California, San Diego; Moores Cancer Center, San Diego, California
- Providence Medical Foundation, Santa Rosa, California
- University of Kansas Medical Center (KUMC), Westwood, Kansas
- Massachusetts General Hospital, Boston, Massachusetts
- Dana Farber Cancer Institute, Boston, Massachusetts
- Karmanos Cancer Institute, Detroit, Michigan
- University of Oklahoma - Health Sciences Center, Oklahoma City, Oklahoma
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee
- Mary Crowley Cancer Research, Dallas, Texas
- START Mountain Region, West Valley City, Utah
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
SBRT With Immunotherapy for Mesothelioma
- Pleural Mesothelial Neoplasm
- Other: Immunotherapy
- Other: Quality-of-Life Assessment
- Radiation: Stereotactic Body Radiation Therapy
- Mayo Clinic in Rochester, Rochester, Minnesota
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma
- Advanced Lung Non-Small Cell Carcinoma
- Advanced Lung Small Cell Carcinoma
- Advanced Pleural Malignant Mesothelioma
- Stage III Lung Cancer AJCC v8
- Stage III Pleural Malignant Mesothelioma AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IV Pleural Malignant Mesothelioma AJCC v8
- Drug: Cisplatin
- Drug: Elimusertib
- University of California Davis Comprehensive Cancer Center, Sacramento, California
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland
- National Institutes of Health Clinical Center, Bethesda, Maryland
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
- University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors
- Non-Small Cell Lung Cancer Squamous
- Non-Small Cell Lung Cancer Non-squamous
- Pleural Mesothelioma
- Drug: MDNA11
- Drug: Pembrolizumab
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
- Providence Saint John's Health Center, Santa Monica, California
- Boca Raton Regional Hospital, Boca Raton, Florida
- Orlando Health Cancer Institute, Orlando, Florida
- Emory - Winship Cancer Institute, Atlanta, Georgia
- Karmanos Cancer Institute, Detroit, Michigan
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
- Mesothelioma
- Drug: Nivolumab Injection
- Greenebaum Comprehensive Cancer Center University of Maryland School of Medicine, Baltimore, Maryland
- Johns Hopkins University, Baltimore, Maryland
- University of Texas M.D. Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Single-Arm, Open-Label, Phase I Trial to Assess the Safety of Genetically Engineered Autologous T Cells Targeting the Cell Surface Antigen Mesothelin With Cell-Intrinsic Checkpoint Inhibition in Patients With Mesothelioma
- Malignant Pleural Mesothelioma (MPM)
- Drug: cyclophosphamide
- Biological: CAR T cells
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults
- Recurrent Malignant Mesothelioma
- Refractory Malignant Mesothelioma
- Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells
- Drug: Cyclophosphamide
- Drug: Etoposide
- M D Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- BAP1 Gene Mutation
- Mesothelioma
- The Ohio State University Wexner Medical Center, Columbus, Ohio
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
- Peritoneal Carcinomatosis
- Peritoneal Mesothelioma
- Procedure: Heated Intraperitonial Chemotherapy
- Drug: Oxaliplatin
- Drug: 5-Fluorouracil
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers
- Mesothelioma
- Biological: Tumor Infiltrating Lymphocytes (TIL)
- Drug: Fludarabine + Cyclophosphamide combination
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Staging Procedures to Diagnose Malignant Pleural Mesothelioma
- Mesothelioma
- Solitary Fibrous Tumor of the Pleura
- Mayo Clinic in Rochester, Rochester, Minnesota
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
- Mesothelioma
- Mesotheliomas Pleural
- Mesothelioma, Malignant
- Mesothelioma Peritoneum
- Non Small Cell Lung Cancer
- Biological: TC-510
- Drug: Fludarabine
- Drug: Cyclophosphamide
- University of California, San Francisco, San Francisco, California
- University of Miami, Miami, Florida
- National Cancer Institute, Bethesda, Maryland
- University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota
- Montefiore Einstein Cancer Center, Bronx, New York
- University of Oklahoma, Oklahoma City, Oklahoma
- Sarah Cannon Research Institute, Nashville, Tennessee
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase 1, Multi-Center, Open-Label, Study to Evaluate the Safety, Tolerability, and PK of VT3989 in Patients With Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the NF2 Gene
- Mesothelioma
- Drug: VT3989
- University of Chicago Medical Center, Chicago, Illinois
- Massachusetts General Hospital, Boston, Massachusetts
- Dana-Farber Cancer Institute, Boston, Massachusetts
- MD Anderson Cancer Center, Houston, Texas
- NEXT Oncology, San Antonio, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
MAGIC-AKI: Magnesium for the Prevention of Hyperthermic Intraoperative Cisplatin-Associated AKI
- Mesothelioma
- Drug: Magnesium sulfate
- Brigham and Women's Hospital, Boston, Massachusetts
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer
- Nsclc
- Mesotheliomas Pleural
- Mesothelioma Peritoneum
- Drug: AMXT1501
- Drug: DFMO
- Mayo Clinic - Arizona, Phoenix, Arizona
- Mayo Clinic - Florida, Jacksonville, Florida
- Mayo Clinic - Minnesota, Rochester, Minnesota
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
- MD Anderson Cancer Center, Houston, Texas
- Fred Hutch Cancer Center - Seattle Cancer Care Alliance, Seattle, Washington
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
- Mesotheliomas Pleural
- Drug: Pembrolizumab
- Procedure: Indocyanine Green (ICG) Image-Guided Surgery
- Drug: Cisplatin
- Drug: Pemetrexed
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
- Mesothelioma (MPM)
- Drug: IK-930
- Massachusetts General Hospital, Boston, Massachusetts
- Start Midwest, Grand Rapids, Michigan
- Memorial Sloan Kettering Cancer Center, New York, New York
- University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania
- Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
- Sarah Cannon Research Institute, Nashville, Tennessee
- MD Anderson Cancer Center, Houston, Texas
- Next Oncology, San Antonio, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
- Mesothelioma
- Pleural Mesothelioma
- Malignant Pleural Mesothelioma
- Drug: Durvalumab
- University of California San Diego, La Jolla, California
- University of Miami, Miami, Florida
- Moffitt Cancer Center, Tampa, Florida
- Emory University, Atlanta, Georgia
- University of Chicago, Chicago, Illinois
- NorthShore University Health System/Kellogg Cancer Center, Evanston, Illinois
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
- Massaschusetts General Hospital, Boston, Massachusetts
- Dana Farber Cancer Institute, Boston, Massachusetts
- University of Michigan, Ann Arbor, Michigan
- Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota
- Morristown Medical/Atlantic Health, Morristown, New Jersey
- Jersey Shore University Medical Center, Neptune, New Jersey
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
- Memorial Sloan Kettering, New York, New York
- University of Cincinnati, Cincinnati, Ohio
- Cleveland Clinic Foundation, Cleveland, Ohio
- The Ohio State University, Columbus, Ohio
- Penn State Cancer Institute, Hershey, Pennsylvania
- Abramson Cancer Cener at Penn Presbyterian Medical Center, Philadelphia, Pennsylvania
- Fox Chase Cancer Center, Philadelphia, Pennsylvania
- Allegheny Cancer Center, Pittsburgh, Pennsylvania
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
- University of Texas Southwestern Medical Center, Dallas, Texas
- Baylor College of Medicine, Houston, Texas
- MD Anderson Cancer Center, Houston, Texas
- University of Virginia, Charlottesville, Virginia
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase I Study of Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
- Mesothelioma
- Biological: LMB-100
- Drug: ipilimumab
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Feasibility and Safety of Neoadjuvant Nivolumab and Chemotherapy for Resectable Malignant Pleural Mesothelioma
- Malignant Pleural Mesothelioma
- Drug: Nivolumab
- Drug: Pemetrexed
- Drug: Cisplatin or Carboplatin
- Memoiral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth, Middletown, New Jersey
- Memorial Sloan Kettering Bergen, Montvale, New Jersey
- Memorial Sloan Kettering Commack, Commack, New York
- Memorial Sloan Kettering Westchester, Harrison, New York
- Memorial Sloan Kettering Cancer Center, New York, New York
- Memorial Sloan Kettering Nassau, Uniondale, New York
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Mesothelioma
- Non Small Cell Lung Cancer
- Drug: NGM707
- University of Southern California, Los Angeles, California
- Hoag Memorial Hospital Presbyterian, Newport Beach, California
- UCLA Medical Center, Santa Monica, California
- Georgetown University Medical Center, Washington, District of Columbia
- Florida Cancer Specialists - Sarasota - SCRI, Sarasota, Florida
- University of Maryland Greenebaum Cancer Center, Baltimore, Maryland
- Dana-Farber Cancer Institute, Boston, Massachusetts
- START Midwest, LLC, Grand Rapids, Michigan
- Nebraska Cancer Specialists, Omaha, Nebraska
- Prisma Health - Upstate, Greenville, South Carolina
- University of Texas Southwestern Medical Center, Dallas, Texas
- MD Anderson Cancer Center, Houston, Texas
- NEXT Oncology, San Antonio, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase I Dose Escalation and Local Control Study of Pembrolizumab + Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma
- Malignant Pleural Mesothelioma
- Drug: Pembrolizumab
- Radiation: IMPRINT
- Memorial Sloan Kettering Basking Ridge (Limited protocol activities), Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey
- Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York
- Memorial Sloan Kettering Cancer Center, New York, New York
- Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Direct Injection of Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
- Malignant Pleural Mesothelioma
- Biological: Safety
- Icahn School of Medicine Mount Sinai, New York, New York
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
- Small Cell Lung Carcinoma
- Small Cell Lung Cancer (SCLC)
- Mesothelioma
- Biological: pembrolizumab
- Call for Information (Investigational Site 0202), Los Angeles, California
- Call for Information (Investigational Site 0017), Los Angeles, California
- Call for Information (Investigational Site 0010), Boston, Massachusetts
- Call for Information (Investigational Site 0008), New Brunswick, New Jersey
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase I/II Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
- Drug: CAR.70/IL15-transduced CB-derived NK cells
- Drug: Fludarabine phosphate
- Drug: Cyclophosphamide
- M D Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- Malignant Pleural Mesothelioma
- Drug: INBRX-109
- HonorHealth Research Institute, Scottsdale, Arizona
- City of Hope, Duarte, California
- Valkyrie Clinical Trials, Los Angeles, California
- University of California, San Diego (UCSD) - Moores Cancer Center, San Diego, California
- Sarcoma Oncology Center, Santa Monica, California
- University of Colorado Hospital, Aurora, Colorado
- Emory University - Winship Cancer Institute, Atlanta, Georgia
- The University of Chicago, Chicago, Illinois
- University of Michigan, Ann Arbor, Michigan
- START Midwest Michigan, PC, Grand Rapids, Michigan
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York
- Cleveland Clinic, Cleveland, Ohio
- Oregon Health & Science University, Portland, Oregon
- University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania
- Vanderbilt University School of Medicine, Nashville, Tennessee
- UT MD Anderson Cancer Center, Houston, Texas
- NEXT Oncology, San Antonio, Texas
- NEXT Oncology - Virginia, Fairfax, Virginia
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors
- Mesothelioma
- Non Small Cell Lung Cancer
- Drug: HFB200301
- Mayo Clinic, Scottsdale, Arizona
- USC/Norris Comprehensive Cancer Center, Los Angeles, California
- Mayo Clinic, Jacksonville, Florida
- Mayo Clinic, Rochester, Minnesota
- Washington University School of Medicine, Saint Louis, Missouri
- The University of Texas, MD Anderson Cancer Center, Houston, Texas
- NEXT Virginia Cancer Specialists, Fairfax, Virginia
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1 Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors
- Non-small Cell Lung Cancer
- Mesothelioma
- Drug: SGN-BB228
- University of California, San Francisco | HDFCCC - Hematopoietic Malignancies, San Francisco, California
- Sarah Cannon Research Institute at HealthONE - Denver, Denver, Colorado
- Northwestern University, Chicago, Illinois
- Massachusetts General Hospital, Boston, Massachusetts
- Dana Farber Cancer Institute, Boston, Massachusetts
- NYU Langone Hospital, New York, New York
- Duke University Medical Center, Durham, North Carolina
- Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington, Seattle, Washington
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
- Lung Cancer
- Mesothelioma
- Diagnostic Test: Biomarker Testing (L)
- Drug: Systemic Treatment (T)
- Teton Cancer Institute, Idaho Falls, Idaho
- Oncology and Hematology of South Texas, Laredo, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Light Dosimetry for Intraoperative Photodynamic Therapy (IO-PDT) With Porfimer Sodium (Photofrin) in Patients With Malignant Mesothelioma or Non-Small Cell Lung Cancer (NSCLC), or Other Malignancies With Pleural Disease - Phase I Study
- Malignant Mesothelioma
- Non-Small Cell Lung Carcinoma
- Pleural Disorder
- Device: Light Dosimetry for Intranoperative Therapy
- Procedure: Photodynamic Therapy
- Drug: Porfimer Sodium
- Roswell Park Cancer Institute, Buffalo, New York
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer
- Mesothelioma
- Mesothelioma, Malignant
- Mesothelioma; Pleura
- Mesotheliomas Pleural
- Mesothelioma Peritoneum
- Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer Metastatic
- Biological: gavo-cel
- Drug: fludarabine
- Drug: cyclophosphamide
- University of California, San Francisco, San Francisco, California
- University of Miami Sylvester Cancer Center, Miami, Florida
- University of Chicago Medical Center, Chicago, Illinois
- National Cancer Institute, Bethesda, Maryland
- Columbia University Medical Center, New York, New York
- Memorial Sloan Kettering Cancer Center, New York, New York
- Duke University, Durham, North Carolina
- University of Pennsylvania, Philadelphia, Pennsylvania
- Sarah Cannon Research Institute, Nashville, Tennessee
- University of Texas MD Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors
- Mesothelioma
- Drug: IAG933
- University of Chicago Medical Center, Chicago, Illinois
- Massachusetts General Hospital Massachusetts General Hospital, Boston, Massachusetts
- Cleveland Clinic Foundation, Cleveland, Ohio
- MD Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed or Refractory Solid Tumors
- Malignant Pleural Mesothelioma
- Biological: CTX131
- Research Site 3, Duarte, California
- Research Site 2, Saint Louis, Missouri
- Research Site 4, Durham, North Carolina
- Research Site 1, Nashville, Tennessee
- Research Site 5, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Inpatient Hospice With Procurement of Tissue on Expiration in Thoracic Malignancies, Bladder Cancer, Ovarian Cancer, Epithelial Cancer and Patients Treated With an Adoptive Cellular Therapy
- Mesothelioma
- Lung Cancers
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
An Observational Study Obtaining Solid Tumor Tissue From Participants and Apheresis for CAR T-Cell Therapy Manufacturing
- Non Small Cell Lung Cancer
- Mesothelioma
- Mesothelioma, Malignant
- Mesothelioma; Lung
- Banner Health, Gilbert, Arizona
- City of Hope, Duarte, California
- University of California San Diego, La Jolla, California
- Stanford University, Palo Alto, California
- UCLA Medical Center, Santa Monica, California
- Mayo Clinic Jacksonville, Jacksonville, Florida
- Moffitt Cancer Center, Tampa, Florida
- Massachusetts General Hospital/Dana Farber Cancer Institute, Boston, Massachusetts
- Mayo Clinic Rochester, Rochester, Minnesota
- Washington University, Saint Louis, Missouri
- NYU Langone Medical Center, New York, New York
- MD Anderson Cancer Center, Houston, Texas
- Fred Hutchinson Cancer Center, Seattle, Washington
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Pilot Window-of-opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
- Pleural Mesothelioma
- Drug: Pembrolizumab
- Drug: Cisplatin and Pemetrexed
- University of Chicago, Chicago, Illinois
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Official Title Neoadjuvant Immunotherapy in Sarcomatoid Mesothelioma
- Pleural Biphasic Mesothelioma
- Biological: Nivolumab
- Biological: Ipilimumab
- Procedure: Surgical Procedure
- Procedure: Computed Tomography
- Procedure: Magnetic Resonance Imaging
- Procedure: Positron Emission Tomography
- Kingman Regional Medical Center, Kingman, Arizona
- PCR Oncology, Arroyo Grande, California
- Beebe South Coastal Health Campus, Frankford, Delaware
- Beebe Medical Center, Lewes, Delaware
- Delaware Clinical and Laboratory Physicians PA, Newark, Delaware
- Helen F Graham Cancer Center, Newark, Delaware
- Medical Oncology Hematology Consultants PA, Newark, Delaware
- Christiana Care Health System-Christiana Hospital, Newark, Delaware
- Beebe Health Campus, Rehoboth Beach, Delaware
- Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware
- Northwestern University, Chicago, Illinois
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois
- Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois
- Northwestern Medicine Cancer Center Delnor, Geneva, Illinois
- Northwestern Medicine Lake Forest Hospital, Lake Forest, Illinois
- Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois
- Christiana Care - Union Hospital, Elkton, Maryland
- Carson Tahoe Regional Medical Center, Carson City, Nevada
- Cancer and Blood Specialists-Henderson, Henderson, Nevada
- Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada
- Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada
- Las Vegas Cancer Center-Henderson, Henderson, Nevada
- OptumCare Cancer Care at Seven Hills, Henderson, Nevada
- Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada
- GenesisCare USA - Henderson, Henderson, Nevada
- Las Vegas Urology - Green Valley, Henderson, Nevada
- Las Vegas Urology - Pebble, Henderson, Nevada
- Urology Specialists of Nevada - Green Valley, Henderson, Nevada
- Las Vegas Urology - Pecos, Las Vegas, Nevada
- OptumCare Cancer Care at Charleston, Las Vegas, Nevada
- University Medical Center of Southern Nevada, Las Vegas, Nevada
- Hope Cancer Care of Nevada, Las Vegas, Nevada
- Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada
- Urology Specialists of Nevada - Central, Las Vegas, Nevada
- GenesisCare USA - Las Vegas, Las Vegas, Nevada
- Sunrise Hospital and Medical Center, Las Vegas, Nevada
- Las Vegas Prostate Cancer Center, Las Vegas, Nevada
- Las Vegas Urology - Sunset, Las Vegas, Nevada
- Urology Specialists of Nevada - Southwest, Las Vegas, Nevada
- Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada
- Ann M Wierman MD LTD, Las Vegas, Nevada
- Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada
- GenesisCare USA - Vegas Tenaya, Las Vegas, Nevada
- Las Vegas Urology - Cathedral Rock, Las Vegas, Nevada
- Las Vegas Urology - Smoke Ranch, Las Vegas, Nevada
- OptumCare Cancer Care at MountainView, Las Vegas, Nevada
- Urology Specialists of Nevada - Northwest, Las Vegas, Nevada
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada
- Comprehensive Cancer Centers of Nevada - Town Center, Las Vegas, Nevada
- Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada
- Summerlin Hospital Medical Center, Las Vegas, Nevada
- Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada
- Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada
- GenesisCare USA - Fort Apache, Las Vegas, Nevada
- OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada
- Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada
- University Cancer Center, Las Vegas, Nevada
- Hope Cancer Care of Nevada-Pahrump, Pahrump, Nevada
- Renown Regional Medical Center, Reno, Nevada
- Saint Mary's Regional Medical Center, Reno, Nevada
- Radiation Oncology Associates, Reno, Nevada
- Duke University Medical Center, Durham, North Carolina
- Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania
- Overlake Medical Center, Bellevue, Washington
- Valley Medical Center, Renton, Washington
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
- Malignant Mesothelioma
- Non-small Cell Lung Cancers
- Drug: PRT3645
- Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut
- AdventHealth Medical Group Oncology Research at Celebration, Celebration, Florida
- Miami Cancer Institute, Miami, Florida
- Florida Cancer Specialists, Sarasota, Florida
- Winship Cancer Institute, Emory University, Atlanta, Georgia
- Laura and Isaac Perlmutter Cancer Center/ NYU Langone Health, New York, New York
- Cleveland Clinic, Cleveland, Ohio
- Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania
- Tennessee Oncology, PLLC, Nashville, Tennessee
- South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas
- NEXT Virginia, Fairfax, Virginia
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma and Other Mesothelin Expressing Cancers
- Mesothelioma
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
- Metastatic Cancer
- Non-small Cell Lung Cancer
- Small Cell Lung Cancer
- Mesothelioma
- Drug: CTX-471
- Ocala Oncology Center, Ocala, Florida
- Hematology Oncology Associates Of The Treasure Coast, Port Saint Lucie, Florida
- Massachusetts General Hospital, Boston, Massachusetts
- Dana-Farber Cancer Institute, Boston, Massachusetts
- Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri
- Hackensack University Medical Center, Hackensack, New Jersey
- Mt Sinai, New York, New York
- Duke University School of Medicine, Durham, North Carolina
- Institute for Translational Oncology Research (ITOR), Greenville, South Carolina
- Mary Crowley Cancer Research, Dallas, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
- Drug: TNG462
- Dana Farber Cancer Institute, Boston, Massachusetts
- New York University Langone Health, New York, New York
- Sarah Cannon Tennessee Oncology, Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center, Houston, Texas
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Feasibility of the LUM Imaging System for Detection of Peritoneal Surface Malignancies
- Peritoneal Metastases
- Combination Product: LUM Imaging System
- Massachusetts General Hospital, Boston, Massachusetts
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
- Mesothelioma
- Non-small Cell Lung Cancer (NSCLC), Non-squamous
- Drug: TAK-500
- Univeristy of Alabama at Birmingham, Birmingham, Alabama
- City of Hope, Duarte, California
- University of California San Diego, La Jolla, California
- University of Colorado - Anschutz Medical Campus - PPDS, Aurora, Colorado
- Sarah Cannon Research Institute, Denver, Colorado
- Sylvester Comprehensive Cancer Center, Miami, Florida
- Northwestern, Chicago, Illinois
- Dana Farber Cancer Institute, Boston, Massachusetts
- Fox Chase Cancer Center, Philadelphia, Pennsylvania
- Sarah Cannon Cancer Institute, Nashville, Tennessee
- START South Texas Accelerated Research Therapeutics, San Antonio, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion
- Mesothelioma
- Non Small Cell Lung Cancer
- Drug: MRTX1719
- Mayo Clinic, Phoenix, Arizona
- Sarah Cannon Research Institute at HealthONE, Denver, Colorado
- Mayo Clinic, Jacksonville, Florida
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida
- Dana Farber Cancer Institute, Boston, Massachusetts
- Mayo Clinic, Rochester, Minnesota
- Memorial Sloan Kettering Cancer Center, New York, New York
- NorthShore Hematology Oncology Associates P.C New York Cancer and Blood Specialists, Port Jefferson Station, New York
- Sarah Cannon Research Institute, Nashville, Tennessee
- MD Anderson Cancer Center, Houston, Texas
- Oncology Consultants, P.A., Houston, Texas
- START Center for Cancer Care, San Antonio, Texas
- NEXT Virginia, Fairfax, Virginia
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Prospective Study of Heated Intra-Peritoneal Chemotherapy (H.I.P.E.C.) With Doxorubicin and Cisplatin in Pediatric Patients With Pelvic and Abdominal Tumors. The TOAST IT Trial (Trial Of Adjuvant Surgical Treatment With Intraperitoneal Chemotherapy)
- Recurrent Malignant Mesothelioma
- Recurrent Primary Peritoneal Carcinoma
- Refractory Malignant Mesothelioma
- Resectable Malignant Mesothelioma
- Resectable Sarcoma
- Drug: Cisplatin
- Procedure: Cytoreductive Surgery
- Drug: Doxorubicin
- Drug: Hyperthermic Intraperitoneal Chemotherapy
- Drug: Sodium Thiosulfate
- Mayo Clinic in Rochester, Rochester, Minnesota
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Utilizing Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC) With Pleural Disease or Malignant Pleural Mesothelioma (MPM) - Phase I Study
- Pleural Disorder
- Drug: Porfimer Sodium
- Procedure: Video-Assisted Thoracic Surgery
- Drug: Photodynamic Therapy
- Device: Intraoperative PDT
- Roswell Park Cancer Institute, Buffalo, New York
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
- Non Small Cell Lung Cancer
- Mesothelioma
- Drug: MT-8421
- The Angeles Clinic, Los Angeles, California
- Horizon Oncology Research, LLC, Lafayette, Indiana
- Washington University in St. Louis, Saint Louis, Missouri
- Weill Cornell Medicine, New York, New York
- NEXT Oncology, Fairfax, Virginia
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Tislelizumab in Patients With Select Advanced Cancers
- Mesothelioma
- Drug: KFA115
- Massachusetts General Hospital ., Boston, Massachusetts
- NYU School of Medicine Langone Health, New York, New York
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes
- Mesothelioma
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Randomized Phase 2 Trial of Radical Pleurectomy and Post-Operative Chemotherapy With or Without Intraoperative Porfimer Sodium -Mediated Photodynamic Therapy for Patients With Epitheliod Malignant Pleural Mesothelioma
- Epitheliod Malignant Pleural Mesothelioma
- Radiation: Photodynamic Therapy
- Procedure: Radical Pleurectomy
- Radiation: Chemotherapy
- Drug: Photofrin 2.0 mg/kg
- Rosewell Park, Buffalo, New York
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
- Procedure: Cytoreductive surgery
- Drug: LMB-100
- Diagnostic Test: Immunohistochemical Assay for Mesothelin
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
- Drug: ENV-101 (taladegib)
- Research Site, Los Angeles, California
- Research Site, San Diego, California
- Research Site, Santa Rosa, California
- Research Site, Tampa, Florida
- Research Site, Zion, Illinois
- Research Site, Covington, Louisiana
- Research Site, Las Vegas, Nevada
- Research Site, New York, New York
- Research Site, Durham, North Carolina
- Research Site, Cincinnati, Ohio
- Research Site, Cleveland, Ohio
- Research Site, Columbus, Ohio
- Research Site, Pittsburgh, Pennsylvania
- Research Site, Nashville, Tennessee
- Research Site, Houston, Texas
- Research Site, Fredericksburg, Virginia
- Research Site, Lynchburg, Virginia
- Research Site, Madison, Wisconsin
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase I Study of Safety, Pharmacokinetic and Efficacy of Orally Administered APG-5918 in Patients With Advanced Solid Tumors or Hematologic Malignancies
- Mesothelioma
- Drug: APG-5918
- Highlands Oncology, Springdale, Arkansas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
- Peritoneal Mesothelioma
- Pleural Mesothelioma
- Small Cell Lung Cancer
- Drug: XmAb20717
- M D Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1/1b Dose Escalation/Expansion Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
- Non-small Cell Lung Cancer
- Mesothelioma
- Drug: NGM831
- NGM Clinical Study Site, Gilbert, Arizona
- NGM Clinical Study Site, Los Angeles, California
- NGM Clinical Study Site, Sarasota, Florida
- NGM Clinical Study Site, Tampa, Florida
- NGM Clinical Study Site, Grand Rapids, Michigan
- NGM Clinical Study Site, New York, New York
- NGM Clinical Study Site, Oklahoma City, Oklahoma
- NGM Clinical Study Site, Austin, Texas
- NGM Clinical Study Site, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types
- Malignant Pleural Mesothelioma (MPM)
- Drug: NX-1607
- City of Hope, Duarte, California
- University of Southern California, Los Angeles, California
- University of California, San Francisco, San Francisco, California
- Memorial Sloan Kettering Cancer Center, New York, New York
- University of North Carolina, Chapel Hill, North Carolina
- MD Anderson Cancer Center, Houston, Texas
- University of Virginia, Charlottesville, Virginia
- Fred Hutchinson Cancer Center, Seattle, Washington
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors
- Drug: IDE397
- Honor Health Research Institute, Scottsdale, Arizona
- City of Hope, Duarte, California
- Indiana University Health Hospital, Indianapolis, Indiana
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
- Dana Farber Cancer Institute, Boston, Massachusetts
- Columbia University Medical Center - Herbert Irving Pavilion, New York, New York
- Weill Cornell Medical College, New York, New York
- Stephenson Cancer Center, Oklahoma City, Oklahoma
- The Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee
- MD Anderson, Houston, Texas
- Next Oncology, San Antonio, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Integrated Cancer Repository for Cancer Research
- Lung Cancer
- Peritoneal Surface Malignancies
- Mesothelioma
- Penrose Cancer Center, Colorado Springs, Colorado
- Porter Adventist Hospital, Denver, Colorado
- Mercy Regional Medical Center, Durango, Colorado
- St. Anthony Hospital, Lakewood, Colorado
- Littleton Cancer Center, Littleton, Colorado
- Longmont Cancer Center, Longmont, Colorado
- Avista Cancer Center, Louisville, Colorado
- Parker Adventist Hospital, Parker, Colorado
- St. Mary Corwin Medical Center, Pueblo, Colorado
- St. Anthony North Cancer Center, Westminster, Colorado
- Florida Hospital Memorial Medical Center, Daytona Beach, Florida
- Florida Hospital DeLand, DeLand, Florida
- Florida Hospital FISH, Orange City, Florida
- Florida Hospital Flagler, Palm Coast, Florida
- Tallahassee Memorial Hospital, Tallahassee, Florida
- Rush-Copley Cancer Care Center, Aurora, Illinois
- Trinity Medical Center, Moline, Illinois
- Rush-Copley Healthcare Center, Yorkville, Illinois
- Parkview Research Center, Fort Wayne, Indiana
- Community Health Network, Indianapolis, Indiana
- Community Cancer Center South, Indianapolis, Indiana
- Community Cancer Center North, Indianapolis, Indiana
- Community Howard Regional Hospital, Kokomo, Indiana
- Methodist Jennie Edmundson Hospital, Council Bluffs, Iowa
- Genesis Medical Center, Davenport, Iowa
- Abben Cancer Center, Spencer, Iowa
- Covenant Medical Center, Inc, Waterloo, Iowa
- Saint Luke's Cancer Instititue - South, Overland Park, Kansas
- Tulane University, New Orleans, Louisiana
- Breast Care Specialists of Maine, Portland, Maine
- Northwest Hospital, Randallstown, Maryland
- William E Kahlert Regional Cancer Center, Westminster, Maryland
- Holyoke Medical Center, Holyoke, Massachusetts
- University of Michigan Health System, Ann Arbor, Michigan
- Riverwood Healthcare Center, Aitkin, Minnesota
- Essentia Health-St. Joseph's Medical Center, Brainerd, Minnesota
- Essentia Health - Duluth Clinic, Duluth, Minnesota
- St. Luke's Hospital of Duluth, Duluth, Minnesota
- Lake Region Healthcare, Fergus Falls, Minnesota
- Avera Cancer Institute- Marshall, Marshall, Minnesota
- Mercy Hospital - Joplin, Joplin, Missouri
- Saint Luke's Cancer Institute, East, Kansas City, Missouri
- Saint Luke's Cancer Institute, Kansas City, Missouri
- Saint Luke's Cancer Institute, Kansas City North, Kansas City, Missouri
- Saint Luke's Cancer Institute, Liberty, Liberty, Missouri
- Heartland Regional Medical Center dba Mosaic Life Care, Saint Joseph, Missouri
- Bozeman Health Deaconess Hospital, Bozeman, Montana
- Logan Health, Kalispell, Montana
- Providence St. Patrick Hospital Montana Cancer Center, Missoula, Montana
- Mary Lanning Healthcare, Morrison Cancer Center, Hastings, Nebraska
- Faith Regional Health Services, Carson Cancer Center, Norfolk, Nebraska
- Great Plains Regional Medical Center, North Platte, Nebraska
- Avera St. Anthony's Hospital, O'Neill, Nebraska
- Methodist Estabrook Cancer Center, Omaha, Nebraska
- Nebraska Methodist Health System, Omaha, Nebraska
- University of Nebraska Medical Center, Omaha, Nebraska
- Regional West Health Services, Scottsbluff, Nebraska
- C.R. Wood Cancer Center, Glens Falls Hospital, Glens Falls, New York
- Faxton St. Luke's Healthcare, Mohawk Valley, Utica, New York
- Cape Fear Valley Health System, Fayetteville, North Carolina
- Essentia Health, Fargo, North Dakota
- Trinity Hospital Cancer Care Center, Minot, North Dakota
- Aultman Alliance Community Hospital, Alliance, Ohio
- Aultman Hospital, Canton, Ohio
- University of Pittsburgh, Pittsburgh, Pennsylvania
- Avera Medical Group Oncology and Hematology Aberdeen, Aberdeen, South Dakota
- Avera Cancer Institute, Mitchell, South Dakota
- Avera Cancer Institute, Sioux Falls, South Dakota
- Sanford Health, Sioux Falls, South Dakota
- Avera Cancer Center Yankton, Yankton, South Dakota
- Avera Sacred Heart Hospital, Yankton, South Dakota
- Yankton Medical Clinic, Yankton, South Dakota
- Rutland Regional Medical Center, Rutland, Vermont
- Mary Washington Hospital, Fredericksburg, Virginia
- Ascension St. Elizabeth Hospital, Appleton, Wisconsin
- Wheaton Franciscan Healthcare - Elmbrook Memorial Hospital, Brookfield, Wisconsin
- Wheaton Franciscan Healthcare, Reiman Cancer Care, Franklin, Wisconsin
- Bellin Memorial Hospital, Green Bay, Wisconsin
- Columbia St. Mary's, Mequon, Wisconsin
- Columbia St. Mary's, Milwaukee, Wisconsin
- Ascension Mercy Hospital, Oshkosh, Wisconsin
- Wheaton Franciscan Healthcare, All Saints, Racine, Wisconsin
- Wheaton Franciscan Healthcare, Wauwatosa Cancer Care, Wauwatosa, Wisconsin
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
FIH Phase 1A /1B Study of AG01 Antibody Against Progranulin/GP88 in Advanced Solid Tumor Malignancies With Expansion Cohorts in Advanced Triple Negative Breast Ca, Hormone Resistant Breast Ca, Non Small Cell Lung Cancer and Mesothelioma
- Non Small Cell Lung Cancer
- Mesothelioma
- Drug: AG-01 Compound
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma
- Mesothelioma
- Drug: Olaparib
- University of Chicago Medical Center, Chicago, Illinois
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma
- Mesothelioma
- Drug: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
- City of Hope National Medical Center, Duarte, California
- Memorial Cancer Institute at Memorial Healthcare Systems, Pembroke Pines, Florida
- Atlantic Health System, Morristown Medical Center, Morristown, New Jersey
- Weill Cornell Medicine, Cornell University, New York, New York
- Gabrail Cancer Center Research, Canton, Ohio
- Erlanger Health System (Hospital); University of Tennessee College of Medicine, Chattanooga, Chattanooga, Tennessee
- The University of Texas MD Anderson Cancer Center, Houston, Texas
- Medical College of Wisconsin, Milwaukee, Wisconsin
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM)
- Pleural Biphasic Mesothelioma
- Pleural Epithelioid Mesothelioma
- Stage I Pleural Malignant Mesothelioma AJCC v8
- Stage IA Pleural Malignant Mesothelioma AJCC v8
- Stage IB Pleural Malignant Mesothelioma AJCC v8
- Stage II Pleural Malignant Mesothelioma AJCC v8
- Stage IIIA Pleural Malignant Mesothelioma AJCC v8
- Drug: Carboplatin
- Drug: Cisplatin
- Procedure: Decortication
- Drug: Pemetrexed
- Drug: Pemetrexed Disodium
- Procedure: Pleurectomy
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
- UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
- Moffitt Cancer Center-International Plaza, Tampa, Florida
- Moffitt Cancer Center - McKinley Campus, Tampa, Florida
- Moffitt Cancer Center, Tampa, Florida
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois
- Brigham and Women's Hospital, Boston, Massachusetts
- Mayo Clinic in Rochester, Rochester, Minnesota
- Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth, Middletown, New Jersey
- Memorial Sloan Kettering Bergen, Montvale, New Jersey
- Memorial Sloan Kettering Commack, Commack, New York
- Memorial Sloan Kettering Westchester, Harrison, New York
- Mount Sinai Hospital, New York, New York
- Memorial Sloan Kettering Cancer Center, New York, New York
- Memorial Sloan Kettering Nassau, Uniondale, New York
- Cleveland Clinic Foundation, Cleveland, Ohio
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio
- MD Anderson in The Woodlands, Conroe, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas
- M D Anderson Cancer Center, Houston, Texas
- MD Anderson West Houston, Houston, Texas
- MD Anderson League City, League City, Texas
- MD Anderson in Sugar Land, Sugar Land, Texas
- Swedish Medical Center-First Hill, Seattle, Washington
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Breathprinting (E-Nose) Technology to Measure Response to Treatment of Malignant Pleural Mesothelioma (MPM) Through MPM-Specific Volatile Organic Compounds Detected in Exhalates
- Malignant Pleural Mesothelioma
- Diagnostic Test: E-Nose testing
- Diagnostic Test: Research blood
- Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Consent Only), Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Consent Only ), Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent Only), Commack, New York
- Memorial Sloan Kettering Westchester (Consent Only), Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
- Memorial Sloan Kettering Nassau (Consent Only), Uniondale, New York
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Prospective Evaluation of Genetic and Epigenetic Alterations in Patients With Thoracic Malignancies
- Malignant Pleural Mesotheliomas NOS
- Lung Cancer NOS
- Thoracic Cancers
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
- Drug: TNG908
- Massachusetts General Hospital, Boston, Massachusetts
- Dana Farber Cancer Institute, Boston, Massachusetts
- Washington University, Saint Louis, Missouri
- Memorial Sloan Kettering Cancer Center, New York, New York
- Sarah Cannon Tennessee Oncology, Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center, Houston, Texas
- NEXT Oncology, Fairfax, Virginia
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1 Study of KZR-261, a Small Molecule Sec61 Inhibitor, in Subjects With Advanced Solid Malignancies
- Drug: KZR-261
- Cedars Sinai Medical Center, Los Angeles, California
- University of California Los Angeles, Los Angeles, California
- Moffitt Cancer Center, Tampa, Florida
- Winship Cancer Institute of Emory University, Atlanta, Georgia
- Fox Chase Cancer Center, Philadelphia, Pennsylvania
- Sara Cannon Research Institution (SCRI) - Tennessee Oncology Nashville, Nashville, Tennessee
- START (South Texas Accelerated Research Therapeutics), San Antonio, Texas
- Virginia Cancer Specialists (VCS), Fairfax, Virginia
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
- Mesothelioma
- National Institutes of Health Clinical Center, Bethesda, Maryland
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
- Peritoneal Malignant Mesothelioma
- Biological: Atezolizumab
- Biological: Bevacizumab
- Procedure: Biospecimen Collection
- Drug: Carboplatin
- Procedure: Computed Tomography
- Procedure: Cytoreductive Surgery
- Drug: Hyperthermic Intraperitoneal Chemotherapy
- Drug: Pemetrexed
- Procedure: Positron Emission Tomography
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois
- Carle at The Riverfront, Danville, Illinois
- Carle Physician Group-Effingham, Effingham, Illinois
- Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois
- Carle Cancer Center, Urbana, Illinois
- The Carle Foundation Hospital, Urbana, Illinois
- University of Kentucky/Markey Cancer Center, Lexington, Kentucky
- Alliance for Clinical Trials in Oncology, Boston, Massachusetts
- Sanford Joe Lueken Cancer Center, Bemidji, Minnesota
- Fairview Southdale Hospital, Edina, Minnesota
- Unity Hospital, Fridley, Minnesota
- Abbott-Northwestern Hospital, Minneapolis, Minnesota
- Mayo Clinic in Rochester, Rochester, Minnesota
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota
- Regions Hospital, Saint Paul, Minnesota
- United Hospital, Saint Paul, Minnesota
- Sanford Bismarck Medical Center, Bismarck, North Dakota
- Sanford Broadway Medical Center, Fargo, North Dakota
- Sanford Roger Maris Cancer Center, Fargo, North Dakota
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
- Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota
- Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota
- MD Anderson in The Woodlands, Conroe, Texas
- M D Anderson Cancer Center, Houston, Texas
- MD Anderson West Houston, Houston, Texas
- MD Anderson League City, League City, Texas
- MD Anderson in Sugar Land, Sugar Land, Texas
- ThedaCare Regional Cancer Center, Appleton, Wisconsin
- Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin
- Marshfield Medical Center-Marshfield, Marshfield, Wisconsin
- Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin
- Marshfield Medical Center-River Region at Stevens Point, Stevens Point, Wisconsin
- Marshfield Medical Center - Weston, Weston, Wisconsin
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
- Mesothelioma
- Other: MPT Test
- Other: CLDN15/VIM Test
- Brigham and Women's Hospital, Boston, Massachusetts
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Subjects With Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma
- Mesothelioma, Malignant
- Biological: SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
- University of Pennsylvania, Philadelphia, Pennsylvania
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors
- Soft Tissue Sarcoma (Excluding GIST)
- Mesothelioma
- Drug: Lurbinectedin
- Drug: Irinotecan
- Massachusetts General Hospital -, Boston, Massachusetts
- Beth Israel Deaconess Medical Center, Boston, Massachusetts
- The University of Texas MD Anderson Cancer Center, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1/1b Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
- Non Small Cell Lung Cancer
- Mesothelioma
- Drug: NGM438
- Yale Cancer Center, New Haven, Connecticut
- Henry Ford Health System, Detroit, Michigan
- START Midwest, Grand Rapids, Michigan
- Mount Sinai Hospital, New York, New York
- MD Anderson, Houston, Texas
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1/2 Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
- Mesothelioma, Malignant
- Drug: CPI-0209
- Winship Cancer Institute of Emory University, Atlanta, Georgia
- University of Chicago Medical Center, Chicago, Illinois
- University of Maryland - Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland
- Massachusetts General Hospital, Boston, Massachusetts
- Dana Farber Cancer Institute, Boston, Massachusetts
- University of Michigan Hospital, Ann Arbor, Michigan
- South Texas Accelerated Research Therapeutics (Start) - Midwest Location, Grand Rapids, Michigan
- Hackensack University Medical Center, Hackensack, New Jersey
- Montefiore Einstein Center for Cancer Care, Bronx, New York
- NYU Langone Medical Center - Laura and Isaac Perlmutter Cancer Center, New York, New York
- Weill Medical College of Cornell University, New York, New York
- University of Cincinnati Medical Center, Cincinnati, Ohio
- South Texas Accelerated Research Therapeutics, San Antonio, Texas
- University of Virginia Health System, Charlottesville, Virginia
- Swedish Cancer Institute, Seattle, Washington
- Fred Hutchinson Cancer, Seattle, Washington
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma
- Mesothelioma
- Solitary Fibrous Tumor of the Pleura
- Mayo Clinic in Rochester, Rochester, Minnesota
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors
- Small-cell Lung Cancer
- Mesothelioma
- Drug: INCB099280
- Dana Farber Cancer Institute, Boston, Massachusetts
- Henry Ford Hospital, Detroit, Michigan
- Upmc Cancercenter, Pittsburgh, Pennsylvania
- Md Anderson Cancer Center, Houston, Texas
- University of Washington, Seattle, Washington
Our Patient Advocates can help you connect with clinical trials
Call (866) 608-8933 to get started
Trial Name
ICARuS II (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multicenter, Randomized Phase II Trial of Normothermic Intraperitoneal Chemotherapy and Intravenous Chemotherapy After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma
- Peritoneal Mesothelioma
- Mesothelioma
- Mesothelioma, Malignant
- Malignant Mesothelioma
- Drug: Pemetrexed
- Drug: Cisplatin
- Drug: Carboplatin
- University of Chicago (Data Collection Only), Chicago, Illinois
- University of Nebraska (Data collection only), Omaha, Nebraska
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey
- Rutgers University (Data Collection Only), New Brunswick, New Jersey
- Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activites), Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York
- Allegheny Health Network (Data Collection Only), Pittsburgh, Pennsylvania
Emerging Mesothelioma Treatments Being Tested in Clinical Trials
Researchers are testing different emerging treatments to see if they can help mesothelioma patients live longer and better manage their symptoms.
Some emerging therapies being tested in clinical trials include:
- Gene therapy: New genes are added to cancer cells to make them easier to attack.
- Mesothelioma vaccines: Certain vaccines may help the immune system destroy mesothelioma cells.
- Photodynamic therapy: A light-activated drug is injected into the body and later “‘turned on” to kill cancer cells.
- Targeted therapy: This form of treatment focuses on attacking cancer cells without damaging the body’s healthy cells.
Results from the CheckMate 743 clinical trial led to the immunotherapy drugs Opdivo® (nivolumab) and Yervoy® (ipilimumab) being approved as a standard treatment for pleural mesothelioma in October 2020.
Research showed that this combination treatment improved patients’ survival time by 4 months. Other immunotherapy combinations continue to be tested in clinical trials for both pleural and peritoneal mesothelioma patients.
How Can Mesothelioma Clinical Trials Help Me?
By joining a clinical trial, you may be able to receive new mesothelioma treatments that aren’t available to the public and that can potentially increase your life expectancy.
Other benefits of mesothelioma clinical trials include:
- Allowing you to receive medical care top mesothelioma doctors at leading cancer centers
- Helping researchers learn more about mesothelioma cancer and improve the lives of future patients
- Opening doors to other treatments if your cancer comes back after a period of remission
- Providing another option if your cancer hasn’t responded to standard treatments
Further, some new treatments being tested in mesothelioma clinical trials may enhance your quality of life by managing symptoms, reducing pain, or minimizing side effects from standard treatments.
Use our Free Doctor Match service to find a specialist who can help you explore all the potential benefits of clinical trials.
Types of Clinical Trials for Mesothelioma
There are different types of mesothelioma clinical trials depending on the goal of the study.
- Prevention trials look at new methods of preventing mesothelioma from developing or returning.
- Screening studies focus on improving or developing new ways to detect mesothelioma before symptoms appear.
- Diagnostic trials are used to evaluate new tests to help detect mesothelioma earlier in patients who are already experiencing symptoms.
- Treatment studies test new treatments as well as updated approaches to surgery, chemotherapy, and other standard mesothelioma treatments.
- Quality of life studies explore ways to manage the symptoms of mesothelioma and the side effects of treatment.
All of these mesothelioma clinical trial types play important roles in helping patients get diagnosed earlier, live longer, and spend more time with their families.
Amy Fair, a nurse with over 20 years of mesothelioma experience, explains what clinical trials are, the types, and how to find them. View Transcript.
Duration: 1 min 31 sec
Besides the standard treatment right now of radiation, surgery, and chemotherapy there are ongoing clinical trials at some facilities that some patients may fit.
Clinical trials are the development of new and novel therapies.
You have to be a candidate and meet certain criterial for clinical trials. Some trials evolve around a certain type of mesothelioma. Some evolve around a certain age group.
There are exciting clinical trials out there now that involved immunotherapy, where they are strengthening and enhancing someone’s immune system to fight the disease. There are target and gene therapies currently in clinical trials that target someone’s DNA make up and molecular studies. These are still currently in several phases of clinical trials.
If you are interested in a clinical trial or your oncologist thinks you’re a candidate for a clinical trial the best way to learn is to start with your oncologist. They should be very knowledgeable about the clinical trials in your area. The National Institute of Health, on their website, has a tremendous amount of knowledge about clinical trials, the different phases that they are in and where these facilities are at that are involved in these clinical trials.
Are Mesothelioma Clinical Trials Safe?
Yes, clinical trials for mesothelioma are highly regulated by the U.S. Food and Drug Administration (FDA) to protect patients’ health and safety.
Key safety measures include:
- Only enrolling patients after a treatment is proven safe in laboratory tests
- Providing a consent form to make sure patients understand any risks and potential side effects of a trial
- Requiring several phases of testing with smaller groups before testing on larger groups of patients
Top mesothelioma cancer centers usually have additional safety measures for clinical trials to prioritize patient safety.
If you choose to join a clinical trial, you’ll receive information about the trial’s purpose, potential benefits, and risks. You’ll be given time to review all of these details before agreeing to start the trial.
Mesothelioma Clinical Trial Phases
Clinical trials for mesothelioma usually have multiple phases. Each phase has a specific purpose and involves a different number of patients.
- Phase I: Researchers test the new treatment on a small group of patients to determine its safety, optimal dosage, and potential side effects.
- Phase II: A larger group of patients is involved to evaluate how effective the treatment is.
- Phase III: Patients are randomly split into groups. Generally, one group will receive the new drug being tested, and the other group will get a placebo or another mesothelioma treatment that’s already been approved. Results from the first three phases are then shared with FDA for review.
- Phase IV: Once a new treatment is FDA approved, phase IV studies may be done to assess the long-term benefits and risks.
Not every mesothelioma clinical trial goes through all four phases. Some trials may be designed as Phase I/II or Phase II/III, depending on the specific goals and needs of the study.
In June 2023, results from a Phase III study showed that pleural mesothelioma patients treated with a combination of chemotherapy and the immunotherapy drug pembrolizumab (Keytruda®) lived longer than patients who received chemotherapy alone.
5 Questions to Ask Your Doctor About Mesothelioma Clinical Trials
If you’re interested in joining a mesothelioma clinical trial, it’s crucial to talk with your doctor so you can make an informed decision about your treatment.
Here are 5 straightforward questions you can ask:
- Has this treatment been used on mesothelioma patients before?
- What are the benefits and risks of participating in this trial?
- How might this study impact my daily life and current treatment plan?
- Where will I need to go to participate in this trial?
- What long-term follow-up care does this clinical trial include?
These questions can help guide your discussion and make sure you leave your appointment with a clear understanding of how the trial will help you.
Download our Free Checklist to see 14 more questions you should ask your doctor about your mesothelioma treatment plan.
What to Expect After Joining a Clinical Trial
After joining a trial, you’ll attend regular check-ups where your medical team will monitor your treatment and ask if you’ve experienced any side effects. You may also have imaging scans or blood tests done during these visits.
Clinical trials for mesothelioma usually take place at cancer hospitals in major cities, so you may need to travel or stay in a hotel depending on where you live.
In some mesothelioma clinical trials, you might be randomly chosen to receive different treatments or a placebo medication. To keep the results of the trial accurate, you won’t know what treatment you’re getting — and your doctor may not know either.
You can drop out of the trial at any time if you experience severe side effects or your health worsens.
After the study is over, you’ll have follow-up appointments where your doctor can see how you’re doing in the long term.
Get Help Finding the Right Mesothelioma Clinical Trial
Mesothelioma Hope firmly believes that clinical trials are the key to developing better treatments that can help patients spend more time with their loved ones.
If you don’t have a medical background, though, it can be difficult to figure out which trials you qualify for. This is where we can make it easier.
Our Patient Advocates have close relationships with mesothelioma specialists and cancer centers and can help recommend a clinical trial based on your age, type of mesothelioma, and other important factors.
Contact us today at (866) 608-8933 or use our Free Doctor Match service to get help finding the right clinical trial.
FAQs About Clinical Trials for Mesothelioma
Are there any clinical trials for mesothelioma?
Yes, there are many clinical trials for mesothelioma that are currently enrolling patients or will be very soon.
According to the National Library of Medicine’s clinical trial database, there are over 80 active mesothelioma clinical trials in the U.S. as of October 2023.
Are there any new treatments for mesothelioma?
Yes, there are several new treatments for mesothelioma that are being investigated in clinical trials.
For example, researchers are looking at targeted therapy as a possible treatment for mesothelioma. Targeted therapy attacks mesothelioma cancer cells without damaging healthy cells.
Scientists are also turning to nature as they develop anticancer medications that may be helpful in the fight against mesothelioma. For example, one drug derived from the periwinkle plant and another from frog eggs have shown promise.
Are there active peritoneal mesothelioma clinical trials in 2023?
Yes. As of October 2023, there are 14 active peritoneal mesothelioma cancer clinical trials in the U.S. according to the National Library of Medicine’s clinical trials database.
One example is the Phase II ICARuS trial being sponsored by Memorial Sloan Kettering Cancer Center. This trial is studying if patients with peritoneal mesothelioma will benefit from additional rounds of chemotherapy after undergoing cytoreductive surgery with heated chemotherapy.
Mesothelioma Hope’s team of Patient Advocates can see if you can join the ICARuS trial or help you find other active clinical trials for peritoneal mesothelioma. Give us a call right now at (866) 608-8933 to get started.
Does it cost money to join clinical trials for mesothelioma?
No, it doesn’t cost you anything to join mesothelioma clinical trials.
Clinical trials are usually sponsored by research institutions, pharmaceutical companies, or government agencies that cover the costs of the study.
You may need to pay for extra expenses like:
- Gas
- Lodging (if needed)
- Parking
- Transportation
However, some or all of these costs may be covered depending on the study or your health insurance plan. It’s also worth asking your mesothelioma doctor whether you can receive a stipend or reimbursement for any out-of-pocket expenses.
What is the latest research on pleural mesothelioma?
According to a September 2023 report, the University of Hawaiʻi Cancer Center has found that targeting a protein released after asbestos exposure (HMGB1) could help stop or slow the growth of mesothelioma.
In addition, early results from the MESOBREATH 5 study show that a breath test could help screen for malignant pleural mesothelioma.
The study results were published in the September 2023 issue of the Journal of Breath Research. However, more research is needed to figure out if breath testing is a reliable screening tool for pleural mesothelioma.
